![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Daewoong Bio Inc. Hwaseong-si Kr, based in South Korea, is a pharmaceutical company.
One of their significant offerings is Ursodeoxycholic acid, Process II, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2012-157 - Rev 00
This Chemical Type CEP, issued on June 19, 2018, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1275 associated with this CEP further emphasizes